Accelerating radiopharmaceutical development.

Your integrated CRO & consulting partner

Meet us at SNMMI | May 30 – June 2, 2026 in Los Angeles, CA, USA

Why partner with BRS?

  • Integrated radiochemistry, translational biology, and pharmacology expertise – tailored to your development program spanning target assessment through IND-enabling strategy

  • Proven track record in advancing radiopharmaceutical programs from early discovery to clinical stage

  • Experienced scientific team — Dedicated experts providing both scientific and strategic guidance throughout your project

  • State-of-the-Art facilities — fully integrated, modern laboratories supporting radiochemical, biological, pharmacological, and analytical workflows

  • Uncompromising quality standards — rigorous, reproducible, and decision-enabling data generation aligned with regulatory expectations

30+

Targets evaluated

Experience across various receptor classes

10+

Discovery programs

Peptide- and antibody-based modalities

10+

Clinical-stage radiopharmaceutical programs

i.e. ATD001, ATT001, SSO120, SSO110

We support your radiopharmaceutical programs with:

  • Target assessment and validation

  • In vitro pharmacology and functional characterization

  • In vivo pharmacology and translational studies

  • Radiolabeling development and optimization

  • Analytical method and formulation development

  • CDMO selection, management and technology transfer

  • Regulatory and IND-enabling support

Your integrated radiopharmaceutical CRO and consulting partner

Our CRO services

From target to IND

Graphic illustrating service offerings supporting radiopharmaceutical development from target discovery to IND readiness.

Our facilities and capabilities

Purpose-built infrastructure integrating radiochemistry, translational biology, and pharmacology workflows for seamless radiopharmaceutical development, including:

  • ■ Radiochemistry, analytical, and formulation development capabilities — enabling radiolabeling optimization, radiochemical purity and stability analysis, and formulation development
  • ■ Biology and pharmacology capabilities — fully equipped for assay development, in vitro pharmacology, and radioactive functional characterization
  • ■ In vivo pharmacology capabilities — enabling biodistribution, efficacy, PK/PD, and dosimetry studies for radiopharmaceutical programs
Scientists working in a radiochemistry laboratory setting handling experimental procedures.
Consulting in scientific and regulatory affairs in radiopharmaceutical development.
Scientists working under a cell culture hood in a radiochemical laboratory environment.
Preparation of tissue slides for immunohistochemical staining procedures.
Scientist analyzing radiochemical purity using iTLC techniques.
Tissue slides stained using immunohistochemistry techniques.
Scientist working with radioactive material inside an isotope hood.
Three people sit at a conference table in a meeting room, discussing in front of a screen showing charts.
Scientist preparing a radiobiological cellular assay in the laboratory.
Consulting in scientific and regulatory affairs in radiopharmaceutical development.
Preparation of radioactive compounds for analytical assessment using iTLC.
Preparation of radioactive cellular samples for live cell imaging analysis.

Licensed for handling therapeutic and diagnostic radionuclides covering alpha-, beta-, and positron-emitting isotopes, including

225Ac, 64Cu, 67Cu, 18F, 67Ga, 68Ge/ 68Ga, 123I, 125I, 111In, 177Lu, 212Pb, 44Sc, 47Sc, 149Tb, 161Tb, 99Mo/99mTc, and 89Zr

Our key development solutions

Radiochemistry & CMC:

    • ■ Radiolabeling process development and optimization for therapeutic and diagnostic radiopharmaceuticals
    • ■ Analytical method and formulation development including radiochemical purity, identity, LogD
    • ■ Radiochemical stability at clinically-relevant activity levels

Pharmacology:

    • ■ Target validation on cells and patient samples
    • ■ In vitro pharmacology and functional characterization, including competition, internalization, retention, and cytotoxicity assays
    • ■ Cellular kinetics and quantitative tissue-binding studies
    • ■ In vivo pharmacology studies

Scientific & Regulatory Consulting:

    • ■ Target and program assessment including biological rationale, IP and competitive landscape evaluation
    • ■ Integrated preclinical, translational, and CMC development strategy
    • ■ CRO/CDMO selection and technical oversight including technology transfer and scale-up coordination
    • ■ Regulatory and IND-enabling support

Our team of interdisciplinary experts

Our multidisciplinary team brings more than 100 years of combined experience across radiochemistry, translational biology, and pharmacology, with a proven track record in advancing radiopharmaceutical and targeted oncology programs from target discovery to first-in-human studies. Having worked closely together for several years, we combine interdisciplinary expertise, agile execution, and translational thinking to support efficient and data-driven program development.

Group photo of an interdisciplinary team of experts in radiochemistry, translational biology, and pharmacology with extensive experience in radiopharmaceutical and targeted oncology development.
Portrait of the co-founders and managing directors with expertise in translational pharmacology and radiochemistry for radiopharmaceutical and targeted oncology development.

Co-Founders & Managing Directors

Anika Jäkel, PhD – Senior translational and nonclinical pharmacology leader with 10+ years in radiopharmaceutical and targeted oncology development

Manuel Sturzbecher-Höhne, PhD – Senior radiochemistry and radiopharmaceutical CMC expert with 15+ years development experience

Our strategic location

Strategically located at the Life Science Campus Berlin-Buch in Germany, the site benefits from its position within a strong network of leading isotope suppliers, radiopharmaceutical companies, and trusted development partners.

Map, Strategic Location of Berlin

Contact us

    Your salutation


    captcha

    Captcha: